Da virkningen af Lucentis var lidt bedre hos patienter, der fik 0, 5 mg, og da de hyppigst forekommende bivirkninger ikke var alvorlige, anbefalede udvalget udstedelse af markedsføringstilladelse for denne dosis.
Since the effectiveness of Lucentis was slightly greater in the patients receiving the 0.5 mg dose and the most common side effects were not serious, the Committee recommended that this dose of Lucentis should be given a marketing authorisation.